CN115947871A - Cd164融合蛋白及其应用 - Google Patents

Cd164融合蛋白及其应用 Download PDF

Info

Publication number
CN115947871A
CN115947871A CN202211627764.4A CN202211627764A CN115947871A CN 115947871 A CN115947871 A CN 115947871A CN 202211627764 A CN202211627764 A CN 202211627764A CN 115947871 A CN115947871 A CN 115947871A
Authority
CN
China
Prior art keywords
fusion protein
polypeptide
mydgf
seq
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202211627764.4A
Other languages
English (en)
Chinese (zh)
Inventor
尹鸿萍
杨美家
缪应花
纪庆超
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Elt Pharmaceutical Research Institute Co ltd
Original Assignee
Jiangsu Elt Pharmaceutical Research Institute Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Elt Pharmaceutical Research Institute Co ltd filed Critical Jiangsu Elt Pharmaceutical Research Institute Co ltd
Publication of CN115947871A publication Critical patent/CN115947871A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202211627764.4A 2020-11-16 2021-11-08 Cd164融合蛋白及其应用 Pending CN115947871A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CNPCT/CN2020/129067 2020-11-16
PCT/CN2020/129067 WO2022099695A1 (en) 2020-11-16 2020-11-16 Cd164 fusion and uses thereof
PCT/CN2021/129378 WO2022100555A1 (en) 2020-11-16 2021-11-08 Cd164 fusion and uses thereof
CN202180009089.6A CN115003702B (zh) 2020-11-16 2021-11-08 Cd164融合蛋白及其应用

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202180009089.6A Division CN115003702B (zh) 2020-11-16 2021-11-08 Cd164融合蛋白及其应用

Publications (1)

Publication Number Publication Date
CN115947871A true CN115947871A (zh) 2023-04-11

Family

ID=81600756

Family Applications (4)

Application Number Title Priority Date Filing Date
CN202211627764.4A Pending CN115947871A (zh) 2020-11-16 2021-11-08 Cd164融合蛋白及其应用
CN202310893591.9A Pending CN117843806A (zh) 2020-11-16 2021-11-08 Cd164融合蛋白及其应用
CN202211627725.4A Pending CN116003634A (zh) 2020-11-16 2021-11-08 Cd164融合蛋白及其应用
CN202180009089.6A Active CN115003702B (zh) 2020-11-16 2021-11-08 Cd164融合蛋白及其应用

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN202310893591.9A Pending CN117843806A (zh) 2020-11-16 2021-11-08 Cd164融合蛋白及其应用
CN202211627725.4A Pending CN116003634A (zh) 2020-11-16 2021-11-08 Cd164融合蛋白及其应用
CN202180009089.6A Active CN115003702B (zh) 2020-11-16 2021-11-08 Cd164融合蛋白及其应用

Country Status (5)

Country Link
US (1) US20240002469A1 (https=)
EP (1) EP4244260A4 (https=)
JP (1) JP2023548945A (https=)
CN (4) CN115947871A (https=)
WO (2) WO2022099695A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022099695A1 (en) * 2020-11-16 2022-05-19 Jiangsu Cell Tech Medical Research Institute Co., Ltd. Cd164 fusion and uses thereof
CN116609531B (zh) * 2023-05-23 2025-10-31 哈尔滨医科大学 Mydgf在治疗血管内模增生的制药和医疗器械中的应用
WO2025047991A1 (en) * 2023-09-01 2025-03-06 Boehringer Ingelheim International Gmbh Myeloid-derived growth factor for use in treating or preventing a liver disorder
CN119798458B (zh) * 2024-12-05 2025-09-26 河南大学 一种dr5和mydgf的融合蛋白及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006077266A1 (en) * 2005-01-24 2006-07-27 Laboratoires Serono S.A. Use of soluble cd164 variants in inflammatory and/or autoimmune disorders
WO2013184939A2 (en) * 2012-06-08 2013-12-12 Alkermes, Inc. Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide
WO2014106839A1 (en) * 2013-01-01 2014-07-10 Kahr Medical Ltd. Stable form of signal converting protein fusion proteins, and methods of use and preparation thereof
CN115003702A (zh) * 2020-11-16 2022-09-02 江苏艾洛特医药研究院有限公司 Cd164融合蛋白及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR045074A1 (es) * 2003-07-23 2005-10-12 Applied Research Systems Uso de cd164 soluble en desordenes inflamatorios y autoinmunes
WO2015200357A2 (en) * 2014-06-23 2015-12-30 Immunomic Therapeutics, Inc. Nucleic acids for treatment of peanut allergies
CN114805532A (zh) * 2014-10-24 2022-07-29 百时美施贵宝公司 修饰的fgf-21多肽及其用途
IL270024B2 (en) * 2017-04-22 2025-04-01 Immunomic Therapeutics Inc LAMP structures and their use in vaccination
CN111544572B (zh) * 2020-05-15 2022-06-07 中山大学 Mydgf蛋白在制备端粒酶表达和细胞衰老调控剂中的应用

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006077266A1 (en) * 2005-01-24 2006-07-27 Laboratoires Serono S.A. Use of soluble cd164 variants in inflammatory and/or autoimmune disorders
WO2013184939A2 (en) * 2012-06-08 2013-12-12 Alkermes, Inc. Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide
WO2014106839A1 (en) * 2013-01-01 2014-07-10 Kahr Medical Ltd. Stable form of signal converting protein fusion proteins, and methods of use and preparation thereof
CN115003702A (zh) * 2020-11-16 2022-09-02 江苏艾洛特医药研究院有限公司 Cd164融合蛋白及其应用
CN116003634A (zh) * 2020-11-16 2023-04-25 江苏艾洛特医药研究院有限公司 Cd164融合蛋白及其应用
CN117843806A (zh) * 2020-11-16 2024-04-09 江苏艾洛特医药研究院有限公司 Cd164融合蛋白及其应用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHAN，J.Y.H.， ET AL: "Relationship between Novel Isoforms，Functionally Important Domains， and Subcellular Distribution of CD164/Endolyn", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 276, no. 3, 10 October 2000 (2000-10-10) *
DOYONNAS，R.， ET AL: "CD164 Monoclonal Antibodies That Block Hemopoietic Progenitor Cell Adhesion and Proliferation Interact with the First Mucin Domain of the CD164 Receptor", THE JOURNAL OF IMMUNOLOGY, vol. 165, 31 December 2000 (2000-12-31) *
邸彩霞;张彦洁;章丽雅;许春娣;夏振炜;周同;: "嗜碱性粒细胞与免疫调节研究进展", 生命科学, no. 07, 15 July 2013 (2013-07-15) *

Also Published As

Publication number Publication date
EP4244260A1 (en) 2023-09-20
EP4244260A4 (en) 2024-05-22
JP2023548945A (ja) 2023-11-21
CN115003702A (zh) 2022-09-02
CN117843806A (zh) 2024-04-09
WO2022100555A1 (en) 2022-05-19
CN115003702B (zh) 2023-08-04
CN116003634A (zh) 2023-04-25
US20240002469A1 (en) 2024-01-04
WO2022099695A1 (en) 2022-05-19

Similar Documents

Publication Publication Date Title
KR102927838B1 (ko) 이중 작용 단백질 및 이를 포함하는 약학적 조성물
CN115003702B (zh) Cd164融合蛋白及其应用
RU2741087C2 (ru) Слитые с fgf21 белки длительного действия и содержащая их фармацевтическая композиция
US10287336B2 (en) Feline erythropoietin receptor agonists
KR102692516B1 (ko) 융합 단백질을 포함하는 간염증, 간섬유화 및 간경화 예방 또는 치료용 약학적 조성물
EA029334B1 (ru) Связывающие сывороточный альбумин молекулы
CN118076373A (zh) 用于联合疗法的包括生长分化因子-15变体和胰高血糖素样肽-1受体激动剂的组合物
EP4582441A2 (en) Multimeric polypeptides and uses thereof
RU2795548C2 (ru) Фармацевтическая композиция для предотвращения или лечения гепатита, фиброза печени и цирроза печени, включающая слитые белки
WO2026078256A1 (en) Cholix-derived delivery construct
WO2025117857A2 (en) Adp-ribosylation factor compositions and methods of use thereof
HK40091844A (zh) 双功能蛋白质和包含其的药物组合物
HK40086042A (zh) 双功能蛋白质和包含其的药物组合物
HK40040781B (en) Long-acting fgf21 fusion proteins and pharmaceutical composition comprising same
HK40012348A (en) Pharmaceutical composition for preventing or treating hepatitis, hepatic fibrosis, and hepatic cirrhosis comprising fusion proteins

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination